Cargando…

1559O Efficacy and toxicity of BNT162b2 vaccine in cancer patients

Detalles Bibliográficos
Autores principales:	Ben-Aharon, I., Waldhorn, I., Holland, R., Peer, A., Halberthal, M., Goshen - Lago, T.G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society for Medical Oncology. Published by Elsevier Ltd. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454389/ http://dx.doi.org/10.1016/j.annonc.2021.08.1552

Ejemplares similares

Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer
por: Goshen-Lago, Tal, et al.
Publicado: (2021)

1609P Cannabis impacts on serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer
por: Zer, A., et al.
Publicado: (2022)

Psychosocial perspectives among cancer patients during the coronavirus disease 2019 (COVID‐19) crisis: An observational longitudinal study
por: Turgeman, Ilit, et al.
Publicado: (2021)

Single BNT162b2 vaccine dose produces seroconversion in under 60 s cohort
por: Shachor-Meyouhas, Yael, et al.
Publicado: (2021)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
por: Herishanu, Yair, et al.
Publicado: (2021)

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
por: Perry, C., et al.
Publicado: (2021)

Response to tozinameran (BNT162b2) booster in twice-vaccinated kidney transplant and maintenance dialysis patients
por: Ben-Dov, Iddo Z., et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
por: Frenck, Robert W., et al.
Publicado: (2021)

The Potential Role of Immune Alteration in the Cancer–COVID19 Equation—A Prospective Longitudinal Study
por: Goshen-Lago, Tal, et al.
Publicado: (2020)

La Europa dividida, 1559-1598 /
por: Elliott, John Huxtable
Publicado: (1976)

Association between IgG antibody levels and adverse events after first and second Bnt162b2 mRNA vaccine doses
por: Braun, Eyal, et al.
Publicado: (2022)

Immunogenicity trends 1 and 3 months after second BNT162B2 vaccination among healthcare workers in Israel
por: Shachor-Meyouhas, Yael, et al.
Publicado: (2022)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
por: Reis, Ben Y., et al.
Publicado: (2021)

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
por: Moreira, Edson D., et al.
Publicado: (2022)

Royauté, Renaissance et Réforme, 1483-1559 /
por: Garrisson, Janine
Publicado: (1991)

Las guerras de religión 1559-1598
por: Livet, Georges
Publicado: (1971)

Actes du IVe centenaire 1559-1959
por: Courvoisier, Jaques
Publicado: (1963)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
por: Benjamini, Ohad, et al.
Publicado: (2021)

Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Acute interstitial nephritis after vaccination with BNT162b2
por: Rieckmann, Sonja, et al.
Publicado: (2022)

Acute myocarditis following administration of BNT162b2 vaccine
por: Habib, Mhd Baraa, et al.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers
por: Hussein, Khetam, et al.
Publicado: (2022)

POS-939 EFFICACY OF BNT162b2 VACCINE IN PATIENTS UNDERGOING HEMODIALYSIS IN NORTH OF PORTUGAL
por: FRANCISCO, J., et al.
Publicado: (2022)

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
por: Shostak, Yael, et al.
Publicado: (2021)

P1584: CELLULAR IMMUNE RESPONSE TO THE BNT162B2 VACCINE IN LYMPHOMA PATIENTS
por: Gurion, R., et al.
Publicado: (2022)

BNT-162b1/clobetasol: Pernio and lack of efficacy: case report
Publicado: (2022)

Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside
por: Levi, Mattan, et al.
Publicado: (2020)

Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients
por: Attias, Philippe, et al.
Publicado: (2021)

Supraclavicular lymphadenopathy secondary to COVID-19 BNT162b2 vaccine
por: Roca, B, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qcnvppjfbkm16e573uajs1lpm7